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The margin of safety of a drug is defined as the ratio between toxicity in animals and safety in humans. 
For intravascular contrast media, the margin of safety is traditionally the ratio between LD50 and diagnostic 
dose, both doses being based on bodyweight. The shift to surface area dramatically reduces this margin 
to unacceptable values. Toxicokinetics, which relates systemic exposure associated with early toxic signs 
in animals to plasma level in man, seems the most accurate and predictive criterion.
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Efficacy and safety are the two clinically relevant 
characteristics of every drug. Safety, indeed, is not an 
absolute value, but is rather a measure of the distance 
between the therapeutic dose and the toxic dose of 
the drug. Thus, toxic doses assessed from pre-clinical 
studies are compared with the dose expected for 
therapy and the ratio between these doses is called 
margin of safety (MS). The greater the ratio, the greater 
the safety (clinical manageability) of the drug.
Intravascular contrast agents are characterized by 
no metabolism, fast excretion and relative biological 
inertness. These favourable properties, coupled with 
their single use in clinical practice, allow that MS is 
simply calculated as the ratio between the end point of 
single-dose toxicity in animals and the diagnostic dose 
in humans. Differences in animal toxicity, expressed 
as LD50, based on body weight have been shown 
to predict different human tolerability of iodinated 
contrast media (1, 2).
Transformation of lethality data from body weight 
to surface area is recommended by Food and Drug 
Administration (FDA) for oncologic drugs, but the 
same approach has also been applied to other 
injectables.
Toxicokinetics, i.e. the determination of drug 
plasma level at nearly toxic doses is also a regulatory 
request to associate systemic exposure in animals with 
threshold doses for tolerability (3, 4).
The objective of this paper was to compare the 
three approaches and assess their predictability for 
human safety of iodinated and paramagnetic contrast 
media.
METHODS
MS for ionic and non-ionic iodinated contrast 
media (CM) as well as paramagnetic CM were 
calculated according to LD50 values based on body 
weight or transformed to surface area or as a ratio 
between maximal plasma levels (Cmax). Intravenous 
LD50 values in mice were obtained from in-house 
historical data or from literature. Standard data for 
animal and human surface areas were as follows: for 
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a 50 kg man surface area was set at 15000 cm2; for 
a 200 g rat surface area was set at 342 cm2; for a 20 
g mouse surface area was set at 73.7 cm2 (5).
Cmax values were obtained from in-house or 
contract laboratory studies conducted by intravenous 
route in different animal species.
Human doses used for the calculation were as 
follows: iodinated CM 10 g (iodine) per person for CM 
of the first generation or 0.7 mg cm-2, 40 g per person 
for CM of the second and third generation or 2.7 mg 
cm-2 (1); paramagnetic CM: 0.1 mmol kg-1.
RESULTS
LD50 approach
When doses are expressed in terms of body weight, 
the margins of safety for ionic contrast media range 
between 7 and 12. For non-ionic contrast media, 
the margin of safety is between 18 and 28. When 
paramagnetic contrast media are considered, the 
LD50 to diagnostic dose ratio is even greater, leading 
to a factor of 100 and more.
Body surface area approach
New concepts in safety evaluation, endorsed by 
regulatory authorities, suggest the surface area as a 
more suitable parameter than body weight to express 
the given dose. The surface area criterion assumes 
that body area more properly represents the area 
where drugs distribute, independently on the weight of 
the organism. This approach was originally developed 
for drugs with pharmacological and toxicological 
properties far different from those of contrast media, 
e.g. anticancer agents. As can be seen from Table 1, 
the transformation to surface area leads the second 
generation of iodinated CM to result in paradoxical 
ratios between lethal doses and the clinical dose. For 
example, diatrizoate would be administered to patients 
at a dose corresponding to 1.3 times the dose which 
is lethal for 50 % of animals. Although this ratio is 
substantially better with iodinated CM of the third 
generation (low-osmolar non ionics), a MS of about 2 
is obviously insufficient to guarantee a safe clinical use 
of all compounds here listed. In addition, considering 
clinical applications for which the standard dose is 
sometimes exceeded (e.g. angiography) this ratio falls 
to 1 or even below, thus coming back to the situation 
of ionics.
Paramagnetic CM remain safer in animals than 
iodinated CM, even after transformation to surface 
area (Table 2).
Toxicokinetics approach
Toxicokinetics is a non-lethal method, which, 
among other pharmacokinetic parameters, determines 
the maximal plasma concentration (Cmax) obtained 
after the administration of the Maximum Tolerated 
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I generation Sodium iodide 0.9* 4.5 0.5 0.8
Uroselectan 2.9* 14.5 1.7 2.5
Methiodal 2.5* 12.5 1.5 2.2
Uroselectan B 3.7 18.5 1.0 1.5
Iodopyracet 2.8 14.0 0.8 1.1
II generation Acetrizoate 6.2 7.8 1.7 0.6
Diatrizoate 7.2 9.0 2.0 0.7
Iothalamate 8.0 10.0 2.2 0.8
Iodamide 8.0 10.0 2.2 0.8
Iocarmate 5.5 6.9 1.5 0.6
Ioxaglate 10.0 12.5 2.7 1.0
III generation Metrizamide 18.1 22.6 4.9 1.8
Iopamidol 21.8 27.3 5.9 2.2
Iohexol 18.4 23.0 5.0 1.9
Iopromide 18.5 20.6 4.5 1.7
Iomeprol 19.9 24.9 5.4 2.0
Iodixanol 21.9 27.4 5.9 2.2
Iotrolan 22.6 27.9 6.1 2.3
* no data available for the mouse, rat data reported.
159
Dose (MTD). The margin of safety is calculated 
by the ratio Cmax animal MTD/Cmax human clinical 
dose, thus providing comparison between actual 
systemic exposure. Margins of safety calculated as 
described above are about 5 and 30 for Iomeron® 
and MultiHance®, respectively. Data for Iomeron® 
and MultiHance®, taken as representative of non-
ionic iodinated CM and paramagnetic CM are shown 
in Tables 2 and 3.








value ratio value ratio value ratio
Iomeron®/ 
mg mL-1 6.5 ≈ 32 5 ≈ 27 4 NA
MultiHance®/
mmol mL-1 0.9 20 22 NA 32 36
* Iomeron® clinical dose: 200 mL of Iomeron 400 per man (1)




Extrapolation of safety data from animals to man 
is often difficult due to differences in metabolism and 
physiology among mammal species. Although in 
regulatory perspective contrast media are considered 
as drugs, the absence of metabolism, free distribution 
to body fluids and the predominant renal excretion 
make the extrapolation somewhat easier in respect 
to true drugs.
In view of the single use of contrast media in 
patients, data from single doses in animals are most 
suitable for the evaluation of margins of safety.
The traditional approach based on LD50 value 
has shown differences in toxicity between classes of 
iodinated contrast media (1) and between compounds 
of the same class (2). This approach however has 
two limitations. The first is practical; LD50 test is no 
longer allowed by health authorities (6), rendering 
unavailable comparison for newly developed contrast 
media. The second is conceptual; the ratio between 
a lethal dose in animals and a diagnostic dose in 
humans will furnish margins of safety in terms of 
lethality, but not in terms of tolerability. Transformation 
to surface area substantially decreases this ratio to 
unacceptable, unrealistic values, when compared to 
clinical occurrence of severe adverse reactions (7). 
Moreover, the cautionary approach to select endpoints 
at lower doses (e.g. MTD, NOAEL, NOEL) further 
decreases the margins of safety below the unit.
In contrast, at these doses toxicokinetics can 
assess actual systemic exposure when the limits of 
tolerability are reached. The ratio between these 
parameters, in particular Cmax, and the anticipated 
human plasma levels are thought to provide a more 
accurate estimation of the margin of safety.
Interestingly, the higher ratio demonstrated by 
MultiHance® (paramagnetic CM) versus Iomeron® 
(iodinated CM) corresponds to greater clinical 
tolerability of MRI CM in respect to iodinated ones 
(8-10). The use of the toxicokinetic approach is thus 
recommended for a reliable assessment of margins 
of safety.
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Table 2  Paramagnetic contrast media. LD50-based margins of safety: body weight (BW) and surface area (SA) approach.
Contrast Medium LD50 (mice) Effective dose (man) Margin of Safety
mmol kg-1 µmol cm-2 mmol kg-1 µmol cm-2 BW SA
MultiHance® 6 3.5 0.05 0.165 120 21.2
Magnevist® 6 3.5 0.1 0.33 60 10.6
ProHance® 14 8.2 0.1 0.33 140 24.8
Data for animal and human surface areas were taken from literature and standardized as follows: man = 50 kg, 15000 cm2 surface area; rat = 
200 g, 342 cm2 surface area (5).
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Sažetak
GRANICA SIGURNOSTI ZA INTRAVASKULARNA KONTRASTNA SREDSTVA: TJELESNA 
TEŽINA, POVRŠINA ILI TOKSIKOKINETIÈKI PRISTUP?
Granica sigurnosti lijeka odreðena je kao odnos izmeðu toksiènosti u životinja i sigurnosti za èovjeka. 
Za intravaskularna kontrastna sredstva granica sigurnosti je poznati odnos izmeðu LD50 vrijednosti i 
dijagnostièke doze, gdje su obje doze temeljene na tjelesnoj težini. Transformacija vrijednosti na površinu 
znaèajno smanjuje granicu sigurnosti do neprihvatljivih vrijednosti. Toksikokinetika, koja povezuje sistemsko 
izlaganje povezano sa ranim znakovima toksiènosti u životinja i s kolièinama u plazmi èovjeka, èini se, 
najtoèniji je i najpredvidljiviji kriterij.
KLJUÈNE RIJEÈI: akutna toksiènost, dijagnostièka doza, LD50, toksikokinetika
REQUESTS FOR REPRINTS:
Simona Bussi, MD, PhD
Bracco Imaging SpA
via Egidio Folli 50, I-20134 Milan, Italy
E-mail: simona.bussi@bracco.com
